Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Ulotaront on ECG Intervals in Schizophrenia
NCT04369391Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jun 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ulotaront in schizophrenia (3 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Placebo-adjusted change-from-baseline QTc interval at 24 hours. Started Jun 2020; status: completed.
02
Drugs
ulotaront
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04369391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04369391.